Sign In
Buy PODD
$143.30
+0.87 (+0.611%)
At Close: Jun 03, 2026
This Healthcare Stock Is the Best Performer in the S&P 500 Tuesday
11:32am, Tuesday, 27'th Aug 2024
Insulet got a key FDA approval for an insulin delivery system.
Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes
04:20pm, Monday, 26'th Aug 2024
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced
These Two Stocks Plunged After Eli Lilly Drug Study Showed Diabetes Promise
05:52pm, Tuesday, 20'th Aug 2024
Shares of Insulet (PODD) and DexCom (DXCM), two companies that provide medical devices for patients managing diabetes, tumbled Tuesday after a study showed that a popular drug made by Eli Lilly (LLY)
Insulet Celebrates Grand Opening of 400,000-square-foot Manufacturing Facility in Malaysia
03:00am, Wednesday, 14'th Aug 2024
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted a g
Insulin Pump Maker Insulet's Stock Slumps on User Growth Concerns
05:51pm, Friday, 09'th Aug 2024
Shares of Insulet (PODD) suffered the heaviest losses of any S&P 500 stock on Friday, dropping 8.8% after the maker of insulin management devices suggested new user growth could be lower than previous
Insulet Is the Worst Stock in S&P 500 Today, Despite Solid Earnings. Here's Why.
01:19pm, Friday, 09'th Aug 2024
The automated insulin technology developer stock is on track for its largest percentage decline since February.
Insulin Pump Maker Insulet's Growth Catalysts Set to Boost Revenue in 2025: Analyst
10:48am, Friday, 09'th Aug 2024
Insulin device maker Insulet Corporation PODD reported a second-quarter adjusted EPS of $0.55 on Thursday, missing the consensus estimate of $0.56. It reported an EPS of $0.38 a year ago.
Insulet (PODD) Q2 Earnings Miss Estimates, '24 Sales View Raised
10:25am, Friday, 09'th Aug 2024
Insulet's (PODD) second-quarter performance benefits from the continued high demand for Omnipod 5.
Insulet Corporation (PODD) Q2 2024 Earnings Call Transcript
08:27pm, Thursday, 08'th Aug 2024
Insulet Corporation (NASDAQ:PODD ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President & Ch
Insulet inventory pressures cloud annual revenue forecast raise
08:07pm, Thursday, 08'th Aug 2024
Insulet Corp PODD.O on Thursday raised its annual revenue growth forecast but pressures over unutilised inventory clouded the upbeat outlook, sending shares of the insulin device maker down about 3.5%
Insulet (PODD) Reports Q2 Earnings: What Key Metrics Have to Say
06:31pm, Thursday, 08'th Aug 2024
Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street e
Insulet (PODD) Q2 Earnings Miss Estimates
06:20pm, Thursday, 08'th Aug 2024
Insulet (PODD) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.38 per share a year ago.
Unlocking Q2 Potential of Insulet (PODD): Exploring Wall Street Estimates for Key Metrics
10:22am, Monday, 05'th Aug 2024
Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
Insulet (PODD) Earnings Expected to Grow: Should You Buy?
11:06am, Thursday, 01'st Aug 2024
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EYE vs. PODD: Which Stock Is the Better Value Option?
12:41pm, Tuesday, 30'th Jul 2024
Investors looking for stocks in the Medical - Products sector might want to consider either National Vision (EYE) or Insulet (PODD). But which of these two stocks presents investors with the better va
